Literature DB >> 22432133

Fitting E(max) models to clinical trial dose-response data.

Simon Kirby1, Phil Brain, Byron Jones.   

Abstract

We consider fitting Emax models to the primary endpoint for a parallel group dose–response clinical trial. Such models can be difficult to fit using Maximum Likelihood if the data give little information about the maximum possible response. Consequently, we consider alternative models that can be derived as limiting cases, which can usually be fitted. Furthermore we propose two model selection procedures for choosing between the different models. These model selection procedures are compared with two model selection procedures which have previously been used. In a simulation study we find that the model selection procedure that performs best depends on the underlying true situation. One of the new model selection procedures gives what may be regarded as the most robust of the procedures.

Mesh:

Year:  2011        PMID: 22432133     DOI: 10.1002/pst.432

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  4 in total

1.  Comparisons of Analysis Methods for Assessment of Pharmacodynamic Interactions Including Design Recommendations.

Authors:  Chunli Chen; Sebastian G Wicha; Rikard Nordgren; Ulrika S H Simonsson
Journal:  AAPS J       Date:  2018-06-21       Impact factor: 4.009

2.  Spline-based procedures for dose-finding studies with active control.

Authors:  Hans-Joachim Helms; Norbert Benda; Jörg Zinserling; Thomas Kneib; Tim Friede
Journal:  Stat Med       Date:  2014-10-16       Impact factor: 2.373

3.  Associations between statins and adverse events in secondary prevention of cardiovascular disease: Pairwise, network, and dose-response meta-analyses of 47 randomized controlled trials.

Authors:  Xinyi Wang; Jingen Li; Tongxin Wang; Zihao Zhang; Qiuyi Li; Dan Ma; Zhuo Chen; Jianqing Ju; Hao Xu; Keji Chen
Journal:  Front Cardiovasc Med       Date:  2022-08-25

4.  Point and Interval Estimators of the Target Dose in Clinical Dose-Finding Studies with Active Control.

Authors:  H-J Helms; N Benda; T Friede
Journal:  J Biopharm Stat       Date:  2014-06-11       Impact factor: 1.051

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.